Fiasp FlexTouch insulin aspart injection

Fiasp (Fast-acting Insulin Aspart) is an ultra-fast acting mealtime insulin used to improve blood sugar levels in adults and children with diabetes. It was developed by Novo Nordisk, a Danish pharmaceutical company that has been a global leader in diabetes care for over a century.

While the brand and original research originated in Denmark, manufacturing occurs across a global network of specialized facilities in countries such as Denmark, France, and Brazil to meet international demand. Novo Nordisk remains the ultimate owner and operator of the brand, continuing its legacy of innovation in metabolic health and chronic disease management.